Martine J. Mellor

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Darren A.E. Cross, Susan Ashton, Serban Ghiorghiu et al. · Cancer Discovery · 2014 · 2.2K citations · Full text

Medicine, Oncology, Pharmacology +13

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

M. Raymond V. Finlay, Mark J. Anderton, Susan Ashton et al. · Journal of Medicinal Chemistry · 2014 · 602 citations · Full text

Medicine, Oncology, Pharmacology +15

AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family

Paul R. Gavine, Lorraine Mooney, Elaine Kilgour et al. · Cancer Research · 2012 · 499 citations

Medicine, Oncology, Pharmacology +16

Quantitation of Endogenous Metabolites in Mouse Tumors Using Mass-Spectrometry Imaging

John G. Swales, Alex Dexter, Grégory Hamm et al. · Analytical Chemistry · 2018 · 76 citations

Life Sciences, Biochemistry, Cancer Biology +17

Irreversible Inhibition of EGFR: Modeling the Combined Pharmacokinetic–Pharmacodynamic Relationship of Osimertinib and Its Active Metabolite AZ5104

James Yates, Susan Ashton, Darren A.E. Cross et al. · Molecular Cancer Therapeutics · 2016 · 50 citations

Medicine, Oncology, Pharmacology +16